JP6176258B2 - ハロゲン置換へテロ環化合物 - Google Patents
ハロゲン置換へテロ環化合物 Download PDFInfo
- Publication number
- JP6176258B2 JP6176258B2 JP2014554626A JP2014554626A JP6176258B2 JP 6176258 B2 JP6176258 B2 JP 6176258B2 JP 2014554626 A JP2014554626 A JP 2014554626A JP 2014554626 A JP2014554626 A JP 2014554626A JP 6176258 B2 JP6176258 B2 JP 6176258B2
- Authority
- JP
- Japan
- Prior art keywords
- biphenyl
- amino
- carbonyl
- ethoxy
- thiophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C*C(C)OC(NC1C=C(*)S[C@]1C(C=CC(c1ccc(C2(CC2)C(O*)=O)cc1)=C)=CC)=O Chemical compound C*C(C)OC(NC1C=C(*)S[C@]1C(C=CC(c1ccc(C2(CC2)C(O*)=O)cc1)=C)=CC)=O 0.000 description 18
- HMGWQYWHVJRYNT-BZNMCICSSA-N CC(NC)OC(Nc1c(/C(/C=C\C(I)=C)=C/C)[s]cc1)=O Chemical compound CC(NC)OC(Nc1c(/C(/C=C\C(I)=C)=C/C)[s]cc1)=O HMGWQYWHVJRYNT-BZNMCICSSA-N 0.000 description 1
- CBDBNBRAIZWCAY-UHFFFAOYSA-N CC(OC(c1c(C)[nH]cc1)=O)=O Chemical compound CC(OC(c1c(C)[nH]cc1)=O)=O CBDBNBRAIZWCAY-UHFFFAOYSA-N 0.000 description 1
- ZOASFSKDAHNLHJ-UHFFFAOYSA-N CC(c(cc1)c(C)cc1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O Chemical compound CC(c(cc1)c(C)cc1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O ZOASFSKDAHNLHJ-UHFFFAOYSA-N 0.000 description 1
- YPIVFRUXQWTSKK-UHFFFAOYSA-N CC(c1c(F)[s]cc1)S Chemical compound CC(c1c(F)[s]cc1)S YPIVFRUXQWTSKK-UHFFFAOYSA-N 0.000 description 1
- PNNDSVLXBCRQNA-UHFFFAOYSA-N CC(c1c[s]cc1Cl)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(F)c1)=O Chemical compound CC(c1c[s]cc1Cl)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(F)c1)=O PNNDSVLXBCRQNA-UHFFFAOYSA-N 0.000 description 1
- VGBRWZTUHMBNKD-UHFFFAOYSA-N CC(c1n[s]cc1)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O Chemical compound CC(c1n[s]cc1)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O VGBRWZTUHMBNKD-UHFFFAOYSA-N 0.000 description 1
- YLJBQAJRNRYUMA-UHFFFAOYSA-N CCCc([s]cc1)c1[F]CC(C)c1c[s]c(CC)c1 Chemical compound CCCc([s]cc1)c1[F]CC(C)c1c[s]c(CC)c1 YLJBQAJRNRYUMA-UHFFFAOYSA-N 0.000 description 1
- ZVPRVKCXBGMSBY-GOSISDBHSA-N CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(ccc(F)c1)c1Cl)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(ccc(F)c1)c1Cl)=O)=O ZVPRVKCXBGMSBY-GOSISDBHSA-N 0.000 description 1
- HOKTYHXKLFRPQN-UHFFFAOYSA-N CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(F)c1)c1C(O)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(c(OC)c1)ccc1-c([s]c(F)c1)c1C(O)=O)=O HOKTYHXKLFRPQN-UHFFFAOYSA-N 0.000 description 1
- SEFQOTNUOAMHBI-GOSISDBHSA-N CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(ccc(F)c1)c1F)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(ccc(F)c1)c1F)=O)=O SEFQOTNUOAMHBI-GOSISDBHSA-N 0.000 description 1
- MOHUBJZWFZFJRS-LJQANCHMSA-N CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(cccc1)c1Cl)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c(cccc1)c1Cl)=O)=O MOHUBJZWFZFJRS-LJQANCHMSA-N 0.000 description 1
- LDBGDLYZTKAKHH-GOSISDBHSA-N CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c1ccc[s]1)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(Cl)c1)c1NC(O[C@H](C)c1ccc[s]1)=O)=O LDBGDLYZTKAKHH-GOSISDBHSA-N 0.000 description 1
- GJVFYKGRBNHQRF-UHFFFAOYSA-N CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(F)c1)c1NC(OC(C)c1c(C)[s]cc1)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(F)c1)c1NC(OC(C)c1c(C)[s]cc1)=O)=O GJVFYKGRBNHQRF-UHFFFAOYSA-N 0.000 description 1
- FBMKIEPFNJQDCO-HXUWFJFHSA-N CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(F)c1)c1NC(O[C@H](C)c1ccccc1)=O)=O Chemical compound CCOC(C1(CC1)c(cc1)ccc1-c(cc1)ccc1-c([s]c(F)c1)c1NC(O[C@H](C)c1ccccc1)=O)=O FBMKIEPFNJQDCO-HXUWFJFHSA-N 0.000 description 1
- CVHOQUMIYLLWOD-MRXNPFEDSA-N C[C@H](c(cc1)cc(F)c1F)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O Chemical compound C[C@H](c(cc1)cc(F)c1F)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O CVHOQUMIYLLWOD-MRXNPFEDSA-N 0.000 description 1
- HVLCPNNJHHQLHI-MRXNPFEDSA-N C[C@H](c(cc1)cc(F)c1F)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(F)c1)=O Chemical compound C[C@H](c(cc1)cc(F)c1F)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(F)c1)=O HVLCPNNJHHQLHI-MRXNPFEDSA-N 0.000 description 1
- PJJWXSANTDRZME-MRXNPFEDSA-N C[C@H](c(ccc(F)c1)c1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O Chemical compound C[C@H](c(ccc(F)c1)c1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(Cl)c1)=O PJJWXSANTDRZME-MRXNPFEDSA-N 0.000 description 1
- AZVGEHGBGRSKSL-LJQANCHMSA-N C[C@H](c1c(C)cccc1)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O Chemical compound C[C@H](c1c(C)cccc1)OC(Nc1c(-c(cc2)ccc2-c2ccc(C3(CC3)C(O)=O)cc2)[s]c(Cl)c1)=O AZVGEHGBGRSKSL-LJQANCHMSA-N 0.000 description 1
- GCKDPEFZAJOXTO-QGZVFWFLSA-N C[C@H](c1ccccc1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(F)c1)=O Chemical compound C[C@H](c1ccccc1F)OC(Nc1c(-c2ccc(-c3ccc(C4(CC4)C(O)=O)cc3)c(OC)c2)[s]c(F)c1)=O GCKDPEFZAJOXTO-QGZVFWFLSA-N 0.000 description 1
- KQKAZNKMCDSPGG-UHFFFAOYSA-N Cc([s]cc1)c1C(N(C)OC)=O Chemical compound Cc([s]cc1)c1C(N(C)OC)=O KQKAZNKMCDSPGG-UHFFFAOYSA-N 0.000 description 1
- GWQOOADXMVQEFT-UHFFFAOYSA-N Cc1ccc(C)[s]1 Chemical compound Cc1ccc(C)[s]1 GWQOOADXMVQEFT-UHFFFAOYSA-N 0.000 description 1
- LBBKWEDRPDGXPM-UHFFFAOYSA-N Cc1ccn[s]1 Chemical compound Cc1ccn[s]1 LBBKWEDRPDGXPM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012286425 | 2012-12-28 | ||
| JP2012286425 | 2012-12-28 | ||
| JP2013097171 | 2013-05-02 | ||
| JP2013097171 | 2013-05-02 | ||
| PCT/JP2013/085277 WO2014104372A1 (ja) | 2012-12-28 | 2013-12-27 | ハロゲン置換へテロ環化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017135811A Division JP6414286B2 (ja) | 2012-12-28 | 2017-07-11 | ハロゲン置換へテロ環化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2014104372A1 JPWO2014104372A1 (ja) | 2017-01-19 |
| JP6176258B2 true JP6176258B2 (ja) | 2017-08-09 |
Family
ID=51021433
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554626A Active JP6176258B2 (ja) | 2012-12-28 | 2013-12-27 | ハロゲン置換へテロ環化合物 |
| JP2017135811A Active JP6414286B2 (ja) | 2012-12-28 | 2017-07-11 | ハロゲン置換へテロ環化合物 |
| JP2018188246A Active JP6569792B2 (ja) | 2012-12-28 | 2018-10-03 | ハロゲン置換へテロ環化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017135811A Active JP6414286B2 (ja) | 2012-12-28 | 2017-07-11 | ハロゲン置換へテロ環化合物 |
| JP2018188246A Active JP6569792B2 (ja) | 2012-12-28 | 2018-10-03 | ハロゲン置換へテロ環化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10000463B2 (enExample) |
| EP (2) | EP2940013B1 (enExample) |
| JP (3) | JP6176258B2 (enExample) |
| KR (1) | KR102189166B1 (enExample) |
| CN (2) | CN104884447B (enExample) |
| AU (1) | AU2013366898B2 (enExample) |
| BR (1) | BR112015015275B1 (enExample) |
| CA (1) | CA2896701C (enExample) |
| DK (2) | DK3360869T3 (enExample) |
| ES (2) | ES2667798T3 (enExample) |
| MX (1) | MX369801B (enExample) |
| RU (2) | RU2756506C2 (enExample) |
| WO (1) | WO2014104372A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2015199234A1 (ja) * | 2014-06-27 | 2017-04-27 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物の塩 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2940013B1 (en) * | 2012-12-28 | 2018-02-21 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound |
| SG11201507459YA (en) | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| JP2014231508A (ja) * | 2013-05-02 | 2014-12-11 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
| JPWO2017086430A1 (ja) * | 2015-11-20 | 2018-09-06 | 宇部興産株式会社 | Ｎａｓｈの治療又は予防のための医薬組成物 |
| IL289951B2 (en) * | 2019-07-30 | 2025-10-01 | Taisho Pharmaceutical Co Ltd | Urea compound as an LPA1 receptor antagonist |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CN111909170B (zh) * | 2020-09-11 | 2022-08-12 | 吉林奥来德光电材料股份有限公司 | 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件 |
| JP7859068B2 (ja) * | 2021-01-28 | 2026-05-15 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物を有効成分として含有する医薬 |
| AU2022273631B2 (en) | 2021-05-11 | 2025-04-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CA3222642A1 (en) | 2022-12-12 | 2024-06-12 | Bmic Llc | Downstream uses for briquettes and other forms of powder from asphalt shingle waste |
| WO2026094986A1 (en) * | 2024-11-01 | 2026-05-07 | Hilung Inc. | Dry powder pharmaceutical composition for inhalation comprising small molecule lpa1 antagonist and process for preparation thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| JP4692281B2 (ja) * | 2003-08-05 | 2011-06-01 | 味の素株式会社 | 新規アゾール化合物 |
| MX2011003383A (es) | 2008-09-29 | 2011-04-21 | Lilly Co Eli | Modulador selectivo del receptor de estrogeno para el tratamiento de osteoartritis. |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス，インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| WO2011091167A2 (en) | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| WO2011159632A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
| CN107721940A (zh) | 2010-12-07 | 2018-02-23 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| WO2012078593A2 (en) | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| CN103596947A (zh) | 2011-04-05 | 2014-02-19 | 艾米拉医药股份有限公司 | 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物 |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| EP2744807A4 (en) | 2011-08-15 | 2015-03-04 | Intermune Inc | COMPOUNDS AS LYSOPHOSPHIC ACID RECEPTOR ANTAGONISTS |
| EP2940013B1 (en) * | 2012-12-28 | 2018-02-21 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound |
-
2013
- 2013-12-27 EP EP13868493.1A patent/EP2940013B1/en active Active
- 2013-12-27 EP EP18157384.1A patent/EP3360869B1/en active Active
- 2013-12-27 WO PCT/JP2013/085277 patent/WO2014104372A1/ja not_active Ceased
- 2013-12-27 KR KR1020157019230A patent/KR102189166B1/ko active Active
- 2013-12-27 JP JP2014554626A patent/JP6176258B2/ja active Active
- 2013-12-27 ES ES13868493.1T patent/ES2667798T3/es active Active
- 2013-12-27 ES ES18157384T patent/ES2825031T3/es active Active
- 2013-12-27 RU RU2018109925A patent/RU2756506C2/ru active
- 2013-12-27 RU RU2015131139A patent/RU2649398C2/ru active
- 2013-12-27 DK DK18157384.1T patent/DK3360869T3/da active
- 2013-12-27 CN CN201380068911.1A patent/CN104884447B/zh active Active
- 2013-12-27 DK DK13868493.1T patent/DK2940013T3/en active
- 2013-12-27 MX MX2015008479A patent/MX369801B/es active IP Right Grant
- 2013-12-27 BR BR112015015275-9A patent/BR112015015275B1/pt active IP Right Grant
- 2013-12-27 AU AU2013366898A patent/AU2013366898B2/en active Active
- 2013-12-27 CN CN201710949188.8A patent/CN107698555B/zh active Active
- 2013-12-27 CA CA2896701A patent/CA2896701C/en active Active
-
2015
- 2015-06-26 US US14/752,623 patent/US10000463B2/en active Active
-
2017
- 2017-07-11 JP JP2017135811A patent/JP6414286B2/ja active Active
-
2018
- 2018-05-08 US US15/974,494 patent/US10597375B2/en active Active
- 2018-10-03 JP JP2018188246A patent/JP6569792B2/ja active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2015199234A1 (ja) * | 2014-06-27 | 2017-04-27 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物の塩 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6569792B2 (ja) | ハロゲン置換へテロ環化合物 | |
| AU2010301675B2 (en) | Novel phenol derivative | |
| JP6579103B2 (ja) | ハロゲン置換へテロ環化合物の塩 | |
| CN109996797B (zh) | 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法 | |
| WO2015000412A1 (zh) | 苯并环丁烯类衍生物、其制备方法及其在医药上的应用 | |
| CA2965467A1 (en) | Kcnq2-5 channel activator | |
| TWI359810B (en) | Carboxylic acid derivative containing thiazole rin | |
| TW201922706A (zh) | 含氮雜芳基化合物及該化合物之醫藥用途 | |
| JP7177577B2 (ja) | 新規な化合物およびこれを含む薬学的組成物 | |
| TW201602089A (zh) | 多環性ｈｅｒｇ活化劑 | |
| JP2022542613A (ja) | ヒトａｔｇｌの阻害剤 | |
| KR100622667B1 (ko) | 나프틸옥시아세트산 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170613 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170626 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6176258 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |